# Suvorexant for Treatment of AUD and PTSD

> **NCT06679062** · PHASE2 · RECRUITING · sponsor: **Pharmacotherapies for Alcohol and Substance Use Disorders Alliance** · enrollment: 76 (estimated)

## Conditions studied

- Alcohol Use Disorder (AUD)
- Post Traumatic Stress Disorder (PTSD)
- Insomnia

## Interventions

- **DRUG:** Suvorexant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06679062
- **Lead sponsor:** Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679062, "Suvorexant for Treatment of AUD and PTSD". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06679062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*